The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Arquist 250 microgram per actuation pressurised inhalation, suspension



Cipla Europe NVPA1963/012/002

Main Information

Trade NameArquist 250 microgram per actuation pressurised inhalation, suspension
Active SubstancesFluticasone propionate
Dosage FormPressurised inhalation, suspension
Licence HolderCipla Europe NV
Licence NumberPA1963/012/002

Group Information

ATC CodeR03BA Glucocorticoids
R03BA05 fluticasone

Status

License statusAuthorised
Licence Issued13/01/2017
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back